Profile of Guillaume Andrieu, research officer in the “Normal and Pathological Lymphoid Differentiation” team led by Vahid Asnafi and Elizabeth Macyntire
His background
Guillaume Andrieu completed his Ph.D. at the University of Toulouse III, focusing on the role of sphingolipid metabolism in chromosomal instability of tumor cells.
During his first postdoctoral fellowship at Boston University, he studied metabolic and epigenetic plasticity in the dissemination and therapeutic resistance of triple-negative breast cancer.
He then joined the Necker-Enfants Malades Institute, within a team affiliated with the Leukemia Institute, to investigate the determinants of therapeutic resistance in hematological cancers, particularly T-cell acute lymphoblastic leukemia (T-ALL).
He was recruited as an INSERM research officer in September 2022.
His research focus areas
Understand the determinants of therapeutic resistance and relapse in T-cell acute lymphoblastic leukemia
Better characterize the biology of cells tolerant to multi-agent chemotherapy that persist under treatment
Exploit vulnerabilities conferred by oncogenic dysregulations in blasts to develop new targeted therapeutic strategies